Increased LGALS3 Expression Independently Predicts Shorter Overall Survival in Patients with the Proneural Subtype of Glioblastoma

Overview

Journal Cancer Med

Specialty Oncology

Date 2019 Mar 9

PMID 30848102

Citations 12

Authors

Xia He

Sunfu Zhang

Junchen Chen

Dekang Li

Affiliations

Soon will be listed here.

Abstract

In the current study, we tried to study the expression of LGALS3 and LGALS3BP, their potential as prognostic markers and the possible genetic/epigenetic mechanisms underlying their dysregulation in different subtypes of glioblastoma (GBM). An in silico retrospective study was performed using large online databases. Results showed that LGALS3 and LGALS3BP were upregulated at both RNA and protein levels in GBM tissue and were generally associated with shorter overall survival (OS) in GBM patients. However, in subgroup analysis, we only found the association in proneural subtype. The copy number alterations did not necessarily lead to LGALS3/LGALS3BP dysregulation. In the proneural subtype of GBM patients, hypermethylation of the two CpG sites (cg19099850 and cg17403875) was associated with significantly lower expression of LGALS3. In univariate and multivariate analysis, LGALS3 expression independently predicted shorter OS in the proneural subtype of GBM (HR: 1.487, 95% CI: 1.229-1.798, P < 0.001), after adjustment of age, gender, IDH1 mutations, temozolomide chemotherapy, radiotherapy and LGALS3BP expression. In comparison, LGALS3BP lost the prognostic value in multivariate analysis. Based on these findings, we infer that LGALS3 expression serves as an independent biomarker of shorter OS in the proneural subtype of GBM, the expression of which might be regulated in an epigenetic manner.

Citing Articles

Crosstalk between genomic variants and DNA methylation in FLT3 mutant acute myeloid leukemia.

Dao B, Trinh V, Nguyen H, Nguyen H, Le T, Luu P Brief Funct Genomics. 2024; 24.

PMID: 38944027 PMC: 11735749. DOI: 10.1093/bfgp/elae028.

Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition.

Xu C, Hou P, Li X, Xiao M, Zhang Z, Li Z Cancer Biol Med. 2024; 21(5).

PMID: 38712813 PMC: 11131044. DOI: 10.20892/j.issn.2095-3941.2023.0510.

CA9, CYFIP2 and LGALS3BP-A Novel Biomarker Panel to Aid Prognostication in Glioma.

Hudson A, Cho A, Colvin E, Hayes S, Wheeler H, Howell V Cancers (Basel). 2024; 16(5).

PMID: 38473425 PMC: 10931055. DOI: 10.3390/cancers16051069.

Mesenchymal ovarian cancer cells promote CD8 T cell exhaustion through the LGALS3-LAG3 axis.

Yakubovich E, Cook D, Rodriguez G, Vanderhyden B NPJ Syst Biol Appl. 2023; 9(1):61.

PMID: 38086828 PMC: 10716312. DOI: 10.1038/s41540-023-00322-4.

SARS-CoV-2 Syncytium under the Radar: Molecular Insights of the Spike-Induced Syncytia and Potential Strategies to Limit SARS-CoV-2 Replication.

Ali H, Naseem A, Siddiqui Z J Clin Med. 2023; 12(18).

PMID: 37763019 PMC: 10531702. DOI: 10.3390/jcm12186079.

References

Fogeron M, Muller H, Schade S, Dreher F, Lehmann V, Kuhnel A . LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells. Nat Commun. 2013; 4:1531. DOI: 10.1038/ncomms2517. View

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M . Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010; 28(12):1248-50. DOI: 10.1038/nbt1210-1248. View

Silverman A, Nakata R, Shimada H, Sposto R, DeClerck Y . A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma. Cancer Res. 2012; 72(9):2228-38. PMC: 3815584. DOI: 10.1158/0008-5472.CAN-11-2165. View

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L . Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2018; 33(1):152. PMC: 5892424. DOI: 10.1016/j.ccell.2017.12.012. View

Shui I, Wong C, Zhao S, Kolb S, Ebot E, Geybels M . Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes. Cancer. 2016; 122(14):2168-77. PMC: 4930391. DOI: 10.1002/cncr.30045. View

He X, Zhang S, Chen J, Li D . Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma. Cancer Med. 2019; 8(5):2031-2040. PMC: 6536958. DOI: 10.1002/cam4.2075. View

Turkalp Z, Karamchandani J, Das S . IDH mutation in glioma: new insights and promises for the future. JAMA Neurol. 2014; 71(10):1319-25. DOI: 10.1001/jamaneurol.2014.1205. View

Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, Nakatani Y . Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol. 1999; 15(1):143-8. DOI: 10.3892/ijo.15.1.143. View

10.

Piccolo E, Tinari N, Semeraro D, Traini S, Fichera I, Cumashi A . LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. J Mol Med (Berl). 2012; 91(1):83-94. DOI: 10.1007/s00109-012-0936-6. View

11.

Inda M, Bonavia R, Seoane J . Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers (Basel). 2014; 6(1):226-39. PMC: 3980595. DOI: 10.3390/cancers6010226. View

12.

Ng K, Kim R, Kesari S, Carter B, Chen C . Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. J Neurooncol. 2011; 107(1):1-12. DOI: 10.1007/s11060-011-0714-2. View

13.

van den Bent M, Erdem-Eraslan L, Idbaih A, de Rooi J, Eilers P, Spliet W . MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res. 2013; 19(19):5513-22. DOI: 10.1158/1078-0432.CCR-13-1157. View

14.

Combs S, Rieken S, Wick W, Abdollahi A, von Deimling A, Debus J . Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?. Radiat Oncol. 2011; 6:115. PMC: 3199258. DOI: 10.1186/1748-717X-6-115. View

15.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

16.

Guan X, Vengoechea J, Zheng S, Sloan A, Chen Y, Brat D . Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One. 2014; 9(3):e91216. PMC: 3948818. DOI: 10.1371/journal.pone.0091216. View

17.

Alves T, Lima F, Assad Kahn S, Lobo D, Dubois L, Soletti R . Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma. Life Sci. 2011; 89(15-16):532-9. DOI: 10.1016/j.lfs.2011.04.022. View

18.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

19.

Martinez R, Rohde V, Schackert G . Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol. 2009; 96(3):321-9. PMC: 2811648. DOI: 10.1007/s11060-009-9967-4. View

20.

Noushmehr H, Weisenberger D, Diefes K, Phillips H, Pujara K, Berman B . Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17(5):510-22. PMC: 2872684. DOI: 10.1016/j.ccr.2010.03.017. View